Saturday, January 30, 2021

The Gamestop Bubble Reveals a

Financial System Totally Out of Touch With Economic Reality

The online pranksters behind the great GameStop bubble of 2021 are probably going to lose a lot of money. But they’ve done the world a service by reminding us of the absurdity of the stock market.


A view of the Wall Street street sign with the New York Stock Exchange during the coronavirus pandemic on May 25, 2020 in New York City. (Photo: Noam Galai/Getty Images)

A view of the Wall Street street sign with the New York Stock Exchange during the coronavirus pandemic on May 25, 2020 in New York City. (Photo: Noam Galai/Getty Images)

First published at Jacobin.

Who knew GameStop would itself become such a game?

Last summer, the video game retailer was seen as a fading brick-and-mortar operation. It was losing money, sales had been shrinking for years, and the stock was trading for around $4 a share. As I’m writing this on the afternoon of Wednesday, January 27, its stock is trading at $339 a share. At the close of trading on Tuesday, it was a mere $148. Not a bad overnight return, 129 percent. Three days earlier, it was at $38. It was up nearly tenfold in less than a week. Why?

To answer that requires explaining the concept of short selling, which most civilians find nearly incomprehensible. A short sale is a bet that a stock (or any other speculative asset, like bonds or gold) is going to decline in price. But to make that bet, you have to sell something you don’t already own, which is not normal behavior. To accomplish this, you have to borrow the stock from somebody who does own it. As with any loan, you have to pay interest on the borrowed asset. And you also have to keep some collateral on deposit with your broker as an assurance you’re good for the money. The hope is that the price will fall, and you can buy the shares—cover the short, in the jargon—at a lower price. Your profit would be the difference between the original sale price and the closing purchase price, minus any interest paid on the borrowed asset.

But what if you’re wrong, and the price rises? Then you’re in trouble. When you buy a stock, your risk is that you could lose the entire purchase price — but no more. With short selling, if you’re wrong, there’s no predetermined limit to how much you can lose if the price keeps rising. And if the price keeps rising, your broker will demand more collateral in the form of real money. You have a choice between giving up—covering the short and taking the loss—or keep pouring more collateral into a losing position in the hope that things will finally turn your way.

Back to GameStop. Last August, the investor Ryan Cohen, who founded the online pet food merchant Chewy and sold it for a handsome profit, started buying GameStop shares. He told the company that it needed to get with the digital age, close a lot of stores, and move online. Investors, expecting a better future for the flailing retailer, snapped up shares, tripling their price by the end of November. That was unjustified optimism, perhaps, but not outlandish. But some hedge funds, notably Melvin Capital Management, began shorting GameStop, believing the tales of recovery were delusional.

Cue the habitués of the subreddit Wall Street Bets, with a user known as DeepFuckingValue among the ringleaders, who began talking up the stock and buying shares. They were motivated not merely by the prospect of making money, but also for the lulz of bankrupting some hedgies. They began buying the stock in size, as they say on Wall Street. The ensuing price rise forced the shorts like Melvin to cover. Their demand for the stock, plus the Redditors’, launched the share price on a moon shot.

GameStop has turned into one of the great bubbles of our time. On Tuesday, January 26, more stock in GameStop was traded than in Apple, the biggest stock of all, with a total market value 108 times the retailer’s. As James Mackintosh of the Wall Street Journal put it, the price action and trading volume together suggest ​widespread disturbance to people’s judgment.”

Bubbles like this always end in a crash, and those Redditors who haven’t sold their shares will be left holding a very depleted bag. (Surprisingly, news that Melvin closed out its short position late on Tuesday seems not to have dampened the party. A bubble usually goes on far longer than mere rationalists can predict.) In the meanwhile, it’s funny to see some Wall Streeters complain that there’s something unfair about this action, since these are the sorts of games they play with each other and the general public all the time. They talk up stocks or talk them down, depending on their interests, and plot against what they see as weak or vulnerable players all the time. It’s just that the speculators with names like DeepFuckingValue who are savaging them for now are the wrong kind of people. They don’t live in Greenwich in houses with twenty-car garages.

Even more amusing are the earnest sorts who think these games somehow pervert the function of the stock market. As Business Insider columnist Josh Barro declared on Twitter: ​I know people think this is fun but — why do we have a stock market? So productive firms can raise capital to do useful things. Detaching stock price from fundamental value (Gamestop is now worth almost as much as Best Buy) makes the markets serve the real economy worse.”

What’s funny about these comments, aside from their earnestness in the midst of low comedy, is that the stock market has almost nothing to do with raising money for productive investment. Almost all the stock that trades on the market, including GameStock, was issued years ago, meaning that companies don’t see a dime of the daily action. Firms do issue stock now and then, in so-called initial public offerings (IPOs), but over the last twenty years, according to finance professor Jay Ritter’s data, IPOs have raised a cumulative total of $657 billion, well under 2 percent of total business investment in things like buildings and equipment over the same period. In the real world, as opposed to Barro’s imagination, firms raise almost all their investment funds internally, through profits. Rather than raising money from shareholders, businesses shovel out vast buckets of money to them. Since 2000, the five hundred large companies that make up the Standard & Poor’s 500 stock index have spent $8.3 trillion buying their own stock to boost its price — over half their profits over the period, and equal to almost 20 percent of business investment over the two decades. Stock buybacks not only make the shareholders happy, but they also fatten CEOs’ paychecks, since bosses these days are paid mainly in stock.

Lulz aside, this drama, like the seemingly endless rise in stock prices since 2009, interrupted briefly by the COVID-19 scare last March, is a sign of a financial system totally out of touch with economic reality. Trillions in government aid to business and Federal Reserve infusions into the financial markets have created a monstrous gusher of money with nowhere to go but speculative assets, at a time when ICUs are at capacity and 24 million people tell Census Bureau interviewers that they’re having trouble getting enough to eat. Barro would do better to worry about that.

Doug Henwood

Doug Henwood edits the  Left Business Observer, a newsletter he founded in 1986, He also hosts Behind the News, a weekly radio show covering economics and politics on KPFA, Berkeley, that is rebroadcast on several other stations across the U.S., and has a worldwide audience via its Internet archive

 PUBLIC OWNERSHIP OF BIG PHARMA NOW!

Oxfam Reaction to 

Johnson & Johnson and Novovax COVID Vaccine Results

WASHINGTON - In response to Johnson & Johnson (JNJ)’s and Novovax release of Phase 3 Trial results of their respective COVID-19 vaccines, Niko Lusiani, Senior Advisor with Oxfam America, made the following statement:

“Today marks yet another hopeful achievement in the fight against the coronavirus. Thanks to tireless scientific efforts, and funding from taxpayers like you and me, these two new vaccines could help turn the corner in the battle against the COVID-19 pandemic. The speed that the virus is mutating is only reinforcing the need for mass-produced vaccines available to everyone, everywhere, as soon as possible.

“As a single-dose, lower-cost vaccine, with corporate commitments to ensure access to all countries, rich and poor alike, the JNJ vaccine candidate could especially provide just the boost the world needs to save lives, rebuild livelihoods and prevent people from falling even deeper into poverty and despair. 

“But no one company alone can produce enough vaccines to bend the curve completely. That’s why every COVID-19 vaccine must be a People’s Vaccine: patent-free, mass produced, distributed fairly based on need, and made available free of charge, to everyone, everywhere.

“A People’s Vaccine, mass produced by qualified manufacturers around the world, is the only way we can make the greatest number of doses in the shortest amount of time and ensure access for everyone. There’s not a minute to waste.

“From development to production to procurement, JNJ’s vaccine was funded largely by the public, so it must be a public good. JNJ’s commitments to more equitable distribution and a non-profit single pandemic price are encouraging steps forward. Next up, the corporation can stake out a position of global leadership in the struggle against COVID by committing to keep its vaccine price at-cost after the pandemic, and sharing its vaccine knowledge, technology, intellectual property, data and know-how to boost supply, reduce price and enhance equity.”

“President Biden has a special opportunity to replace the narrow vaccine nationalism of the recent past with the global vaccine solidarity of the future. That’s why more than 100 high-level leaders from public health, faith-based, racial justice, and labor organizations, joined former members of Congress, economists and artists in a public letter calling on President Biden to make every COVID-19 vaccine a People’s Vaccine: a global public good, freely and fairly available to all, prioritizing those most in need here at home and around the world.”

###

 PUBLIC OWNERSHIP OF BIG PHARMA NOW!

As Fears Grow Over Covid Vaccine Delays, Watchdog Asks: 'Why Are We Allowing Big Pharma's Patents to Artificially Limit Supply?'

"It's just wrong that big business is deciding who gets vaccinated, with zero transparency. We must scrap patents and massively scale up production globally."


Published on
by
People queue in bad weather to enter a Covid-19 vaccination centre in Folkestone, Kent, during England's third national lockdown to curb the spread of coronavirus on Friday January 29, 2021.

People queue in bad weather to enter a Covid-19 vaccination centre in Folkestone, Kent, during England's third national lockdown to curb the spread of coronavirus on Friday January 29, 2021. (Photo: Gareth Fuller/PA Images via Getty Images)

"Could you patent the sun?"

That was Jonas Salk's famous response when asked in 1955 who owned the patent for one of the first successful polio vaccines, which the American virologist was instrumental in developing.

"Every available manufacturer in the world should be producing these vaccines, and governments should be doing whatever it takes to increase manufacturing capacity for the whole world." 
—Nick Dearden, Global Justice Now

Salk believed the vaccine should belong to "the people," not profit-seeking corporations—an argument with particular resonance during the present coronavirus pandemic, as artificial scarcity created by government-granted patent protections leaves hundreds of millions of people in developing nations without access to effective vaccines and pits people in wealthier nations against one another in a life-or-death battle for vials.

With the global coronavirus death toll now over the two million mark and new mutations spreading, the European Union and Britain in recent days have descended into a bitter and potentially destructive fight over vaccine shipments, leading the 27-nation E.U. to threaten export restrictions on vaccines amid growing public anger over production delays and shortages.

"The notoriously tricky manufacturing of vaccines is only part of the problem," the New York Times noted in a Wednesday report on what it called the "vaccine wars" raging in Europe. "Public health experts say the entire global system of buying doses, pitting one country against another with little regard for equity, is unfit to the task of ending a pandemic that respects no borders."

Nick Dearden, director of U.K.-based advocacy group Global Justice Now, warned in a statement Friday morning that the ongoing vaccine dispute between Britain and the E.U. "will be the first of many and could lead the world down a dangerous path" unless "we fundamentally change who controls the supply of vaccines," which have been developed with the help of large infusions of public funding.

"There is a lot of focus on what will happen to the current limited doses, but the bigger question is why are we allowing Big Pharma's patents to artificially limit the supply of these vital vaccines?" Dearden asked. "Every available manufacturer in the world should be producing these vaccines, and governments should be doing whatever it takes to increase manufacturing capacity for the whole world."

As the Times reported Wednesday, "Pfizer informed the European Union and other countries outside the United States this month that it had to drastically cut its vaccine deliveries until mid-February to upgrade its plants in order to ramp up output, adding to the severe supply problems facing the region."

"But it was AstraZeneca's sudden announcement last week that it would cut deliveries in February and March by 60 percent, that really upended European Union vaccination plans," the Times explained. "Many countries had built their strategies around expectations of millions of those doses of that vaccine, which is cheaper and easier to store than others, in the first quarter of the year. AstraZeneca said it was having production troubles at one of its factories."

Instead of allowing "a handful of massively wealthy corporations" to dictate production and decide who receives vaccines first, Dearden argued that governments should immediately suspend patent protections "and work together to ramp up supply now."

A coalition of nearly 100 countries led by India and South Africa—with the backing of the World Health Organization (WHO)—is currently petitioning the World Trade Organization (WTO) to do just that, calling for a suspension of certain intellectual property rights in the interest of ensuring global vaccine access as poor nations are increasingly at risk of being left behind.

But the international effort has been stymied by opposition from the governments of the United States and Europe, which continue to insist—in the face of rapidly mounting evidence to the contrary—that strict patent protections are "part of the solution rather than an obstacle."

"I don't understand how governments of the world are able to outsource their responsibility for public health to a few companies that are able to hold them all ransom," Mustaqeem De Gama, counselor at the South African mission to the WTO, lamented last November.

In a blog post earlier this week, Dean Baker of the Center for Economic and Policy Research (CEPR) argued that the "logical path" toward ensuring equitable global vaccine distribution "would have been to open-source all research on treatments and vaccines, both so that progress could be made as quickly as possible, and also intellectual property rights would not be an obstacle to large-scale production throughout the world."

"The big problem, of course, is that going this route of open-source research and international cooperation could call into question the merits of patent monopoly financing of prescription drug research," Baker noted. "After all, if publicly funded open-source research proved to be the best mechanism for financing the development of drugs and vaccines in a pandemic, maybe this would be the case more generally."

 PUBLIC OWNERSHIP OF BIG PHARMA NOW!

Why Has the Vaccine Rollout Been So Slow? Answer: Big Pharma Patent Monopolies

In a normal flu season, close to 2 million shots are given every day, without any heroic efforts by the government. Given the urgency of getting the pandemic under control, it is hard to understand why we could not have administered shots at this pace, if not considerably faster.

Published on
by
A woman walks past a "Covid-19 vaccine not yet available" sign outside a store in Arlington, Virginia on December 1, 2020. (Photo: Olivier Douliery/AFP via Getty Images)

A woman walks past a "Covid-19 vaccine not yet available" sign outside a store in Arlington, Virginia on December 1, 2020. (Photo: Olivier Douliery/AFP via Getty Images)

The vaccine rollout process has been painfully slow in the United States. More than 40 days after the first vaccine was approved for emergency use by the Food and Drug Administration, just over 6.0 percent of our population has been vaccinated. And that is with just the first shot, very few having gotten the two shots needed to hit the targeted levels of immunity. Thankfully the pace of the vaccination program is picking up, both as kinks are worked out and now that we have an administration that cares about getting people vaccinated.

But we still have to ask why the process has been so slow. We have an obvious answer in the United States, the Trump administration basically said that distribution wasn’t its problem. As Donald Trump once tweeted, he considered the distribution process the responsibility of the states and gave the order “get it done.”

If we can explain the failure to have more rapid distribution in the United States on Trump’s Keystone Cops crew, what explains the failures in other wealthy countries? As bad as the U.S. has done so far, we have vaccinated a larger share of our population than any country in Europe with the exception of the United Kingdom. That’s right, countries like Denmark, France, and even Germany have done worse in vaccinating their populations than the United States. And these countries ostensibly have competent leaders and all have national health care systems. Nonetheless, they have done worse far worse in the case of France and Germany, than Donald Trump’s clown show.

The Vaccine Agenda if Saving Lives Was the Priority

The pandemic is a worldwide crisis, that requires a worldwide solution. This is a classic case where there are enormous benefits from collective action and few downsides. This is not a case, like seizing oil or other natural resources, where if the United States gets more, everyone else gets less and vice-versa. Sharing knowledge about vaccines, treatments, and best practices for prevention is costless and the whole world benefits if the pandemic can be contained as quickly as possible. This point is being driven home as new strains develop through mutation, which may spread more quickly and possibly be more deadly and vaccine-resistant.

The logical path would have been to open-source all research on treatments and vaccines, both so that progress could be made as quickly as possible, and also intellectual property rights would not be an obstacle to large-scale production throughout the world. This would have required some collective agreement where countries agreed to both put up some amount of research funding, presumably based on size and per capita income, and also that all findings, including results from clinical trials, would be quickly posted on the web. This way, the information would be quickly shared so that researchers and public health experts everywhere could benefit.

This sort of international cooperation was obviously not on Donald Trump’s agenda. Mr. “America First!” was not interested in the possibility that we might better be able to tame the pandemic if we acted in cooperation with other countries. But it wasn’t just Donald Trump who rejected the idea of open research and international cooperation, it really wasn’t on the agenda of any prominent politician, including progressives like Bernie Sanders and Elizabeth Warren. It was an issue in the scientific community, but as we know, people in policy circles don’t take science seriously. (I describe a mechanism for advanced funding of open-source research in chapter 5 of Rigged [it’s free].)  

The big problem, of course, is that going this route of open-source research and international cooperation could call into question the merits of patent monopoly financing of prescription drug research. After all, if publicly funded open-source research proved to be the best mechanism for financing the development of drugs and vaccines in a pandemic, maybe this would be the case more generally. And, no one in a position of power in American politics wanted to take this risk of a bad example.  

Making the Best of the Single Country Route

If we had gone the route of publicly funded open-source research, then the scientific community would have access to all the clinical trial results of all the vaccines as they become available. This would mean that countries could decide which vaccines they wanted to use based on the data.[1] They could also begin to produce and stockpile large quantities of vaccines, as soon as they entered Phase 3 trials. Incredibly, it seems no country has done this.

Just to be clear, there was no physical obstacle to producing billions of vaccines by the end of 2020. If we can build one factory to produce these vaccines, we can build ten factories.

While we could not know that a vaccine entering Phase 3 trials will subsequently be shown to be safe and effective, the advantages of having a large stockpile available that can be quickly distributed swamp the potential costs of buying large quantities of a vaccine that is not approved. Suppose the United States had produced 400 million doses of a vaccine that turned out not to be effective. With the production costs of a vaccine at around $2 per shot, this would mean that we had wasted $800 million. With the country seeing more than 4,000 deaths a day at the peak of the pandemic and the economic losses from the pandemic running into the trillions, the risk of spending $800 million on an ineffective vaccine seems rather trivial.  

For whatever reason, no country went this stockpile route. Just to be clear, there was no physical obstacle to producing billions of vaccines by the end of 2020. If we can build one factory to produce these vaccines, we can build ten factories. If some of the inputs are in short supply, we can build more factories to produce the inputs. There may be questions of patent rights, but that is different than a question of physical limitations.

But apart from the physical availability of the vaccines, there is also the issue of distributing the vaccine and actually getting the shots in peoples’ arms. It seems that, rather than making preparations in advance, most governments acted like the approval of the vaccine was a surprise and only began to make plans for distribution after the fact.

This is really mind-boggling. While we could not know the exact date a vaccine would be approved, it was known that several vaccines were approaching the endpoints of their Phase 3 trials. In that situation, it is hard to understand why governments would not have been crafting detailed plans for how they would get the vaccines to people as quickly as possible, once the authorization had been made.

This would have meant pre-positioning stockpiles as close as possible to inoculation locations. These locations should also have been selected in advance, with plans to have the necessary personnel available to oversee and administer the shots. There are reports that there are shortages of people trained in administering the shots. The fall would have been a great time to train enough people to administer the vaccine.

In a normal flu season, close to 2 million shots are given every day, without any heroic efforts by the government. Given the urgency of getting the pandemic under control, it is hard to understand why we could not have administered shots at this pace, if not considerably faster. The fact that it wasn’t just the United States that missed this standard, but also every country in Europe, indicates an enormous failure of public health systems.  

As a result of these failures, we will see millions of preventable infections and tens of thousands of avoidable deaths. We will also see hundreds of billions of dollars of lost economic output, as the pandemic will disrupt the economy for longer than necessary.

Will There be a Penalty for Failure?

I raise this issue primarily because I’m fairly confident the answer is no. To be clear, my point is that not being prepared for the mass distribution of vaccines as soon as they were approved was a massive policy failure both in the United States and Europe. I have no idea who was responsible for the failure, but it was presumably several high-level people in each country. In any reasonable world, these people would suffer serious career consequences for not getting the vaccines out quickly.

I am not making this point out of any vindictiveness—I don’t know any of these people—I just want to see high-end workers held to the same job performance standards as those lower down the ladder. The dishwasher that breaks the dishes gets fired. The custodian who doesn’t clean the toilet gets fired. Why doesn’t the person who messes up vaccine distribution pay a price?

Unfortunately, the lack of accountability at the top is the rule, not the exception. To take my favorite example in economics, to my knowledge Carmen Reinhart and Ken Rogoff suffered no consequences (other than embarrassment) for their famous Excel spreadsheet error. To remind people, this was when they produced a paper that purported to show that countries with debt-GDP ratios above 90 percent took a huge hit to GDP growth. It turned out that this result was driven entirely by an error in a spreadsheet. When the error was corrected, the result went away.

Reinhart and Rogoff’s paper was used to justify austerity policies in Europe and the United States. As a result of these policies millions of people needlessly went unemployed and many important areas of social spending, like education and health care, saw serious cuts.

Reinhart and Rogoff’s error was surely an honest mistake (they are both competent economists, who could have come up with much better ways to fake results if that was their intention), but their failure to check their numbers was inexcusable. As they explained after the error was uncovered, the mistake was the result of rushing to finish a paper for a conference presentation.

Mistakes like that happen, and most of us have committed similar errors. That is not a big deal. The big deal was that, as their work was being cited by members of Congress, finance ministers, and central bankers, that it never occurred to them to review their rushed work.  

Should Reinhart and Rogoff have lost their tenured positions at Harvard? Perhaps this would have been appropriate. At the very least, they should have lost their named chairs, after all, many people had their lives ruined in part because they couldn’t be bothered to check their numbers.

Accountability for Our Elites

As I have written endlessly, we have seen a massive upward redistribution of income in the United States over the last four decades. Other countries have also seen increases in inequality over this period, although not as large. I have argued that this upward redistribution was by design, not the natural development of the economy, but for this issue, the question of causes is beside the point.

It is appalling that we have structured the economy in such a way that the elites can be protected from consequences for even the most extreme failures.

The people who have been able to enjoy rising incomes and financial security over the last four decades ostensibly justify their better position by their greater contribution to the economy and society. But when you mess up in your job in big ways that lead to major costs to the economy and society, that claim doesn’t hold water.

We have seen a massive rise in right-wing populism where large numbers of less-educated workers reject the elites and all their claims about the world. When we have massive elite mess-ups, as we now see with vaccine distribution, and there are zero consequences for those responsible, this has to contribute to the resentment of the less advantaged.

It is appalling that we have structured the economy in such a way that the elites can be protected from consequences for even the most extreme failures. The fact so few elite types even see this as a problem (seen any columns in the NYT calling for firing?) shows that the populists have a real case. The economy is rigged against the left behind, and the people that control major news outlets, which include many self-described liberals or progressives, won’t even talk about it.

[1] China and Russia have not been open with the clinical trial data for their vaccines. Presumably, if they had committed to transparency in an agreement, they would abide by their commitment, but obviously, we cannot be certain this would be the case.

 PUBLIC OWNERSHIP OF BIG PHARMA NOW!

New Report From Rep. Katie Porter Reveals How Big Pharma Pursues 'Killer Profits' at the Expense of Americans' Health

"It's time we reevaluate the standards for approving these mergers. It's time we pass legislation to lower drug prices. And it's time we rethink the structure of leadership at big pharmaceutical companies."



A new report from Rep. Katie Porter (D-Calif.) takes pharmaceutical companies to task for their merger and acquisition activities. (Photo: Tom Williams/CQ-Roll Call, Inc.)

A new report from Rep. Katie Porter (D-Calif.) reveals how Big Pharma uses mergers and acquisitions to increase profits at the expense of Americans' healthcare. (Photo: Tom Williams/CQ-Roll Call, Inc.) 

Rep. Katie Porter on Friday published a damning report revealing the devastating effects of Big Pharma mergers and acquisitions on U.S. healthcare, and recommending steps Congress should take to enact "comprehensive, urgent reform" of an integral part of a broken healthcare system. 

"In 2018, the year that Donald Trump's tax giveaway to the wealthy went into effect, 12 of the biggest pharmaceutical companies spent more money on stock buybacks than on research and development."
—Report

The report, entitled Killer Profits: How Big Pharma Takeovers Destroy Innovation and Harm Patients, begins by noting that "in just 10 years, the number of large, international pharmaceutical companies decreased six-fold, from 60 to only 10."

While pharmaceutical executives often attempt to portray such consolidation as a means to increase operational efficiency, the report states that "digging a level deeper 'exposes a troubling industry-wide trend of billions of dollars of corporate resources going toward acquiring other pharmaceutical corporations with patent-protected blockbuster drugs instead of putting those resources toward' discovery of new drugs."

Merger and acquisition (M&A) deals are often executed to "boost stock prices," to "stop competitors," and to "acquire an innovative blockbuster drug with an enormous prospective revenue stream." 

"Instead of spending on innovation, Big Pharma is hoarding its money for salaries and dividends," the report says, "all while swallowing smaller companies, thus making the marketplace far less competitive." 

The report calls M&As "just the tip of the iceberg of pharmaceutical companies' anti-competitive, profit-driven behaviors":

Pharmaceutical companies often claim that lowering the prices of prescription drugs in the United States would devastate innovation. Yet, as prices have skyrocketed over the last few decades, these same companies' investment in research and development have failed to match this same pace. Instead, they've dedicated more and more of their funds to enrich shareholders or to purchase other companies to eliminate competition.

"In 2018, the year that [former President] Donald Trump's tax giveaway to the wealthy went into effect, 12 of the biggest pharmaceutical companies spent more money on stock buybacks than on research and development," the report notes.

Some key findings from the report:

  • Big pharmaceutical companies are not responsible for most major breakthroughs in new drugs. Rather, innovation is driven in small firms, which are often spun off of taxpayer-funded academic research. These small labs are then purchased by giant firms after they've assumed the risk needed to develop a blockbuster drug;
  • Instead of producing lifesaving drugs for diseases with few or no cures, large pharmaceutical companies often focus on small, incremental changes to existing drugs in order to kill off generic threats to their government-granted monopoly patents; and
  • Mergers in the pharmaceutical industry have had an overall negative effect on innovation, taking what little competition existed in the industry and completely destroying it.

"Competition is central to capitalism," Porter said in a press release introducing the report. "As our report shows, Big Pharma has little incentive to invest in new, critically needed drugs. Instead, pharmaceutical giants are free to devote their resources to acquiring smaller companies that might otherwise force them to compete."

"Lives are on the line; it's clear the federal government needs to reform how it evaluates healthcare mergers and patent abuses," Porter added. 

To that end, Porter's report recommends the following actions:

"It's time we reevaluate the standards for approving these mergers," the report concludes. "It's time we pass legislation to lower drug prices. And it's time we rethink the structure of leadership at big pharmaceutical companies. Together, these strategies can help us bring more innovative, and critically needed, cures and treatments to market."